Početna stranicaGLTO • NASDAQ
add
Galecto Inc
23,01 $
Poslije radnog vremena:(6,13 %)+1,41
24,42 $
Zatvoreno: 31. pro, 18:34:04 GMT -5 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
22,31 $
Dnevni raspon
22,33 $ - 24,75 $
Godišnji raspon
2,01 $ - 38,33 $
Tržišna kapitalizacija
36,64 mil. USD
Prosječna količina
148,14 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2025.info | Godišnja promjena |
|---|---|---|
Prihod | — | — |
Operativni troškovi | 3,16 mil. | −17,81 % |
Neto dohodak | −3,13 mil. | 19,31 % |
Neto profitabilnost | — | — |
Zarada po dionici | — | — |
EBITDA | −3,15 mil. | 17,81 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 7,61 mil. | −61,35 % |
Ukupna imovina | 10,74 mil. | −54,07 % |
Ukupne obveze | 2,73 mil. | 11,80 % |
Ukupni kapital | 8,01 mil. | — |
Dionice u optjecaju | 1,33 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 4,44 | — |
Povrat imovine | −64,60 % | — |
Povrat kapitala | −82,59 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −3,13 mil. | 19,31 % |
Gotovina od poslovanja | −2,62 mil. | 28,35 % |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | −2,60 mil. | 18,18 % |
Slobodan tok novca | −1,17 mil. | 43,71 % |
Više
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Glavni izvršni direktor
Osnovano
2011
Web-lokacija
Zaposlenici
5
